Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Statements of Operations [Abstract]
Product sales, net	$ 8,648,242	$ 8,378,094
Cost of products sold	3,055,991	3,016,642
Gross profit	5,592,251	5,361,452
Selling, general and administrative expenses	5,930,625	6,445,001
Research and development expenses	181,979	140,053
Total operating expenses	6,112,604	6,585,054
Loss from operations	(520,353)	(1,223,602)
Other income (expense)
Interest income	34	35
Interest expense	(175,905)	(131,838)
Amortized debt issuance	(3,065)	(5,296)
Loss on Earnings from Medical Joint Venture	(171,016)	(121,399)
Total other expense	(349,952)	(258,498)
Net loss applicable to common stockholders	$ (870,306)	$ (1,482,100)
Loss per share applicable to common stockholders - basic and diluted	$ (0.05)	$ (0.10)
Weighted average shares outstanding and to be issued - basic and diluted	16,080,474	15,174,893